Compare BDL & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDL | CYPH |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6M | 73.4M |
| IPO Year | 1995 | N/A |
| Metric | BDL | CYPH |
|---|---|---|
| Price | $31.33 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.4K | ★ 2.2M |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ 49.72 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $205,248,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $72.86 | ★ N/A |
| Revenue Growth | ★ 8.99 | N/A |
| 52 Week Low | $22.61 | $0.50 |
| 52 Week High | $35.98 | $3.70 |
| Indicator | BDL | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 53.99 |
| Support Level | $29.75 | $0.87 |
| Resistance Level | $33.61 | $1.31 |
| Average True Range (ATR) | 1.07 | 0.11 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 40.26 | 37.05 |
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.